Current issues in pharmaceutical reimbursement

American Journal of Health-System Pharmacy

Volumn 65, Issue 2 SUPPL. 1, 2008, Pages

  Fijalka, Steven ^a,b   Fye, David ^c   Johnson, Philip E ^d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Health Alliance of Greater Cincinnati   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Charity; Clinical studies; Errors, medication; Health benefit programs; Hematopoietic agents; Pharmacists; Pharmacy; Reimbursement

Indexed keywords

ANTIANEMIC AGENT;

CLINICAL RESEARCH; CONFERENCE PAPER; DRUG COST; DRUG SAFETY; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH SERVICE; MEDICAID; MEDICARE; MEDICATION ERROR; PATIENT; PATIENT ASSESSMENT; PATIENT SAFETY; PHARMACIST; PHARMACY; POLICY; PRIORITY JOURNAL; PROFIT; REIMBURSEMENT;

EID: 38349144365     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070620     Document Type: Conference Paper

References (32)

1. Bower A. Specialty drug costs continue to rise; employees hit with higher premiums. Biotechnol Healthc. December 2005. http://www. biotechnologyhealthcare.com/journal/fulltext/2/6/BH0206018.pdf (accessed 2007 Jul 13).
2. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm. 2006; 12(9):736-44.
3. Joint Commission. Facts about the 2007 National Patient Safety Goals. http://www. jointcommission.org/PatientSafety/National PatientSafetyGoals/ 07_npsg_facts.htm (accessed 2007 Jul 14).
4. Centers for Medicare and Medicaid Services. Proposed decision memo for erythropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N). http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=203 (accessed 2007 Jul 11).
5. U.S. Food and Drug Administration. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. http://www.fda.gov/cder/ drug/InfoSheets/HCP/RHE2007HCP.htm (accessed 2007 Jul 11).
6. U.S. Food and Drug Administration. 2007 safety alert: Aranesp (darbepoetin alfa). http://www.fda.gov/medwatch/safety/2007/ Aranesp_DHCP_012707.htm (accessed 2007 Jul 11).
7. Straus DJ, Testa MA, Sarokhan BJ et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006; 107:1909-17.
8. National Comprehensive Cancer Network. Practice guidelines in oncology: cancer-and treatment-related anemia. v.3.2007. http://www.nccn.org/ professionals/physician_gls/PDF/anemia.pdf (accessed 2007 Jul 11).
9. Epogen package insert. Thousand Oaks, CA: Amgen; March 2007.
10. Aranesp package insert. Thousand Oaks, CA: Amgen; May 2007.
11. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer. 1998; 83:2588-96.
12. Crémieux PY, Barrett B, Anderson K et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol. 2000; 18:2755-61.
13. DeVita VT, ed. Cancer: Principles and Practice of Oncology. Baltimore, MD: Lippincott, Williams and Wilkins; 2004.
14. Mercuriali F, Inghilleri G. Transfusion risks and limitations. Minerva Anestesiol. 1999; 65:286-92.
15. Gleason K, Tigue C, Yarnold P et al. Recombinant erythropoietin (Epo)/darbepoetin (Darb) associated venous thromboembolism (VTE) in the oncology setting: findings from the Research on Adverse Drug Events And Reports (RADAR) project. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: abstract 2552. http://www.asco.org/ portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/ ?vgnextoid=76f8201eb61a7010VgnVCM 100000ed730ad1RCRDandvmview=abst_ detail_viewandconfID=47andabstractID= 35508 (accessed 2007 Jul 11).
16. Glaspy J, Smith R, Aapro M et al. Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. Presented at the American Association for Cancer Research Annual Meeting, Los Angeles, CA, April 16, 2007.
17. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002; 20:4083-107.
18. The Kaiser Commission on Medicaid and the Uninsured. The uninsured and their access to health care. October 2006. http://www.kff.org/uninsured/upload/ The-Uninsured-and-Their-Access-to-Health-Care-Oct-2004. pdf (accessed 2007 Jul 12).
19. Johnson PE. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails. Am J Health-Syst Pharm. 2006; 63(suppl 7):S13-7.
20. American Cancer Society. Clinical trials: what you need to know. http://www.cancer.org/docroot/ETO/content/ETO_6_3_Clinical_Trials_-
21. Centers for Medicare and Medicaid Services. NCA tracking sheet for clinical trial policy (CAG-00071R). http://www.cms.hhs.gov/mcd/ viewtrackingsheet.asp?id=186 (accessed 2007 Jul 12).
22. Centers for Medicare and Medicaid Services. Decision memo for clinical trial policy (CAG-00071R). https://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id= 186 (accessed 2007 Jul 17).
23. The Henry J. Kaiser Family Foundation and Health Research and Educational Trust. Survey of employer health benefits 2006. September 26, 2006. http://kff.org/insurance/7527/upload/7561.pdf (accessed 2007 Jul 16).
24. To Err Is Human: Building a Safer Health System. 2000. http://www.nap.edu/books/0309068371/html/ (accessed 2007 Jul 16).
25. Crossing the Quality Chasm: A New Health System for the 21st Century. 2001. http://www.nap.edu/books/0309072808/html/ (accessed 2007 Jul 16).
26. Dunn JD. Pharmacy management approach: how do we align all the incentives? J Manag Care Pharm. 2007; 13(2 suppl S-b): S16-19.
27. Centers for Medicare and Medicaid Services. Hospital Quality Alliance. http://www.cms.hhs.gov/HospitalQualityInits/15_HospitalQualityAlliance.asp (accessed 2007 Jul 16).
28. Centers for Medicare and Medicaid Services. Hospital Quality Alliance (HQA) 2004-2007 measure build out table. http://www.cms.hhs.gov/ HospitalQualityInits/downloads/HospitalHQA2004_2007200512.pdf (accessed 2007 Jul 16).
29. Lee D. Hospital-borne ailments face Medicare budget ax. The Indianapolis Star, May 22, 2007.
30. Glickman SW, Ou FS, DeLong ER et al. Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA. 2007; 297:2373-80.
31. Centers for Medicare and Medicaid Services. Eliminating serious, preventable, and costly medical errors - never events. http://www.cms.hhs.gov/ apps/media/press/release.asp?Counter=1863 (accessed 2007 Jul 9).
32. Simone JV. Simone's OncOpinion on cancer refugees (3/10/07 issue). Oncology Times, vol. XXIX, no.9, page 3, May 10, 2007. www.oncology-times.com/pt/re/oncotimes/pdfhandler.00130989-200705100-00001. pdf;jsessionid=GFQfyJxZxmGhMjC4DGW 3JssQnlVy5tskJ7dn5yQSW2Rm1xkGCT92!434772722!181195629!8091!-1 (accessed 2007 Jul 16).